Download PDF
Semin Neurol 2001; 21(1): 041-048
DOI: 10.1055/s-2001-13118
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Diagnosis and Management of Progressive Supranuclear Palsy

Irene Litvan
  • Neuropharmacology Unit, Defense & Veteran Head Injury Program, Henry M. Jackson Foundation, Bethesda, Maryland
Further Information

Publication History

Publication Date:
31 December 2001 (online)

    Permissions and Reprints

ABSTRACT

Because of the relevance of an early and accurate diagnosis for prognosis, management, and participation of patients in research, the classical clinical features-features that should raise suspicion of progressive supranuclear palsy (PSP) and those that should make the diagnosis of PSP unlikely-are discussed in this article. The accuracy of currently used clinical diagnostic criteria and the role of laboratory investigations in the diagnosis of PSP are reviewed. New terminology for the clinical diagnostic criteria for PSP is proposed. The main neuropathologic and neurochemical features supporting current main symptomatic and hypothesized experimental biologic therapies are suggested.

KEYWORD

Progressive supranuclear palsy - diagnosis - treatment - atypical Parkinsonian disorders

REFERENCES

  • 1 Steele J C, Richardson J C, Olszewski J. Progressive supranuclear palsy.  Arch Neurol . 1964;  10 333-359
    CrossrefPubMedGoogle Scholar
  • 2 Steele J. Introduction. In: Litvan I, Agid Y, eds. Progressive Supranuclear Palsy: Clinical and Research Approaches New York: Oxford University Press 1992: 3-14
    Google Scholar
  • 3 Litvan I, Agid Y, Jankovic J. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome).  Neurology . 1996;  46 922-930
    CrossrefPubMedGoogle Scholar
  • 4 Golbe L I, Davis P H, Schoenberg B S, Duvoisin R C. Prevalence and natural history of progressive supranuclear palsy.  Neurology . 1988;  38 1031-1034
    CrossrefPubMedGoogle Scholar
  • 5 Bower J H, Maraganore D M, McDonnell S K, Rocca W A. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmstead County, Minnesota, 1976 to 1990.  Neurology . 1997;  49 1284-1288
    CrossrefPubMedGoogle Scholar
  • 6 Schrag A, Ben-Shlomo Y, Quinn N P. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study.  Lancet . 1999;  354 1771-1775
    CrossrefPubMedGoogle Scholar
  • 7 Litvan I, Mangone C A, McKee A. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study.  J Neurol Neurosurg Psychiatry . 1996;  60 615-620
    PubMedGoogle Scholar
  • 8 Colosimo C, Albanese A, Hughes A J, de Bruin M V, Lees A J. Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease.  Arch Neurol . 1995;  52 294-298
    PubMedGoogle Scholar
  • 9 Collins S J, Ahlskog J E, Parisi J E, Maraganore D M. Progressive supranuclear palsy: neuropathologically based diagnostic criteria.  J Neurol Neurosurg Psychiatry . 1995;  58 167-173
    CrossrefPubMedGoogle Scholar
  • 10 Litvan I, Grimes D A, Lang A E. Phenotypes and prognosis: clinicopathologic studies of corticobasal degeneration. In: Litvan I, Goetz CK, Lang AE, eds. Advances in Neurology Philadelphia: Lippincott Williams & Wilkins; 2000: 183-196
    Google Scholar
  • 11 Nuwer M. Progressive supranuclear palsy despite normal eye movements.  Arch Neurol . 1981;  38 784
    PubMedGoogle Scholar
  • 12 Dubas F, Gray F, Escourolle R. Maladie de Steele-Richardson-Olszewski sans ophtalmoplégie.  Rev Neurol . 1983;  139 407-416
    PubMedGoogle Scholar
  • 13 Matsuo H, Takashima H, Kishikawa M. Pure akinesia: an atypical manifestation of progressive supranuclear palsy.  J Neurol Neurosurg Psychiatry . 1991;  54 397-400
    CrossrefPubMedGoogle Scholar
  • 14 Riley D E, Fogt N, Leigh R J. The syndrome of ``pure akinesia'' and its relationship to progressive supranuclear palsy.  Neurology . 1994;  44 1025-1029
    PubMedGoogle Scholar
  • 15 Leiguarda R C, Pramstaller P P, Merello M. Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism.  Brain . 1997;  120 75-90
    CrossrefPubMedGoogle Scholar
  • 16 Bergeron C, Pollanen M S, Weyer L, Lang A E. Cortical degeneration in progressive supranuclear palsy: a comparison with cortical-basal ganglionic degeneration.  J Neuropathol Exp Neurol . 1997;  56 726-734
    PubMedGoogle Scholar
  • 17 Litvan I, Agid Y, Calne D. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Report of the NINDS-SPSP International Workshop.  Neurology . 1996;  47 1-9
    CrossrefPubMedGoogle Scholar
  • 18 Lopez O L, Litvan I, Catt K E. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias.  Neurology . 1999;  53 1292-1299
    PubMedGoogle Scholar
  • 19 Hauw J J, Daniel S E, Dickson D. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).  Neurology . 1994;  44 2015-2019
    CrossrefPubMedGoogle Scholar
  • 20 Litvan I, Hauw J J, Bartko J J. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders.  J Neuropathol Exp Neurol . 1996;  55 97-105
    CrossrefPubMedGoogle Scholar
  • 21 Sergeant N, Wattez A, Delacourte A. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively ``exon 10'' isoforms.  J Neurochem . 1999;  72 1243-1249
    CrossrefPubMedGoogle Scholar
  • 22 Spillantini M G, Crowther R A, Jakes R, Hasegawa M, Goedert M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies.  Proc Natl Acad Sci U S A . 1998;  95 7737-7741
    CrossrefPubMedGoogle Scholar
  • 23 Goedert M. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.  Philos Trans R Soc Lond B Biol Sci . 1999;  354 1101-1118
    PubMedGoogle Scholar
  • 24 Vidailhet M, Rivaud S, Gouider-Khouja N. Eye movements in parkinsonian syndromes.  Ann Neurol . 1994;  35 420-426
    CrossrefPubMedGoogle Scholar
  • 25 Dubois B, Pillon B, Legault F, Agid Y, Lhermitte F. Slowing of cognitive processing in progressive supranuclear palsy: a comparison with Parkinson's disease.  Arch Neurol . 1988;  45 1194-1199
    CrossrefPubMedGoogle Scholar
  • 26 Pierrot-Deseilligny C, Turell E, Penet C. Increased wave P 300 latency in progressive supranuclear palsy.  J Neurol Neurosurg Psychiatry . 1989;  52 656-658
    PubMedGoogle Scholar
  • 27 Johnson R J, Litvan I, Grafman J. Progressive supranuclear palsy: altered sensory processing leads to degraded cognition.  Neurology . 1991;  41 1257-1262
    CrossrefPubMedGoogle Scholar
  • 28 Johnson R J. Event-related brain potentials. In: Litvan I, Agid Y, eds. Progressive Supranuclear Palsy: Clinical and Research Approaches New York: Oxford University Press 1992: 122-154
    Google Scholar
  • 29 Savoiardo M, Girotti F, Strada L, Ciceri E. Magnetic resonance imaging in progressive supranuclear palsy and other parkinsonian disorders.  J Neural Transm Suppl . 1994;  42 93-110
    PubMedGoogle Scholar
  • 30 Schrag A, Good C D, Miszkiel K. Differentiation of atypical parkinsonian syndromes with routine MRI.  Neurology . 2000;  54 697-702
    CrossrefPubMedGoogle Scholar
  • 31 Tedeschi G, Litvan I, Bonavita S. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration.  Brain . 1997;  120 1541-1552
    CrossrefPubMedGoogle Scholar
  • 32 D'Antona R, Baron J C, Samson Y. Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy.  Brain . 1985;  108 785-799
    PubMedGoogle Scholar
  • 33 Foster N L, Gilman S, Berent S. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography.  Ann Neurol . 1988;  24 399-406
    CrossrefPubMedGoogle Scholar
  • 34 Blin J, Baron J C, Dubois B. Positron emission tomography study in progressive supranuclear palsy: brain hypometabolic pattern and clinicometabolic correlations.  Arch Neurol . 1990;  47 747-752
    CrossrefPubMedGoogle Scholar
  • 35 Verny M, Duyckaerts C, Agid Y, Hauw J J. The significance of cortical pathology in progressive supranuclear palsy: clinicopathological data in 10 cases.  Brain . 1996;  119 1123-1136
    PubMedGoogle Scholar
  • 36 De Volder G A, Francard J, Laterre C. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration.  Ann Neurol . 1989;  26 239-247
    CrossrefPubMedGoogle Scholar
  • 37 Baron J C, Maziere B, Loc'h C. Loss of striatal [76Br] bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy.  J Cereb Blood Flow Metab . 1986;  6 131-136
    PubMedGoogle Scholar
  • 38 Leenders K L, Frackowiak R S, Lees A J. Steele-Richardson-Olszewski syndrome: brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography.  Brain . 1988;  111 615-630
    PubMedGoogle Scholar
  • 39 Brooks D J, Ibanez V, Sawle G V. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.  Ann Neurol . 1990;  28 547-555
    CrossrefPubMedGoogle Scholar
  • 40 Brooks D J. PET studies in progressive supranuclear palsy.  J Neural Transm Suppl . 1994;  42 119-134
    PubMedGoogle Scholar
  • 41 Agid Y, Javoy-Agid F, Ruberg M. Progressive supranuclear palsy: anatomoclinical and biochemical considerations.  Adv Neurol . 1987;  45 191-206
    PubMedGoogle Scholar
  • 42 Litvan I. Progressive supranuclear palsy revisited.  Acta Neurol Scand . 1998;  98 73-84
    CrossrefPubMedGoogle Scholar
  • 43 Kompoliti K, Goetz C G, Litvan I, Jellinger K, Verny M. Pharmacological therapy in progressive supranuclear palsy.  Arch Neurol . 1998;  55 1099-1102
    CrossrefPubMedGoogle Scholar
  • 44 Jankovic J. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy.  Neurology . 1983;  33 505-507
    PubMedGoogle Scholar
  • 45 Weiner W J, Minagar A, Shulman L M. Pramipexole in progressive supranuclear palsy.  Neurology . 1999;  52 873-874
    CrossrefPubMedGoogle Scholar
  • 46 Litvan I, Chase T N. Traditional and experimental therapeutic approaches. In: Litvan I, Agid Y, eds. Progressive Supranuclear Palsy: Clinical and Research Approaches New York: Oxford University Press 1992: 254-269
    Google Scholar
  • 47 Litvan I. Cholinergic approaches to the treatment of progressive supranuclear palsy.  J Neural Transm Suppl . 1994;  42 275-281
    PubMedGoogle Scholar
  • 48 Litvan I, Blesa R, Clark K. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.  Ann Neurol . 1994;  36 55-61
    CrossrefPubMedGoogle Scholar
  • 49 Ghika J, Tennis M, Hoffman E, Schoenfeld D, Growdon J. Idazoxan treatment in progressive supranuclear palsy.  Neurology . 1991;  41 986-991
    PubMedGoogle Scholar
  • 50 Conrad C, Andreadis A, Trojanowski J Q. Genetic evidence for the involvement of tau in progressive supranuclear palsy.  Ann Neurol . 1997;  41 277-281
    CrossrefPubMedGoogle Scholar
  • 51 Baker M, Litvan I, Houlden H. Association of an extended haplotype in the tau gene with progressive supranuclear palsy.  Hum Mol Genet . 1999;  8 711-715
    CrossrefPubMedGoogle Scholar
  • 52 Hutton M, Lendon C L, Rizzu P. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17.  Nature . 1998;  393 702-705
    CrossrefPubMedGoogle Scholar
  • 53 Odetti P, Garibaldi S, Norese R. Lipoperoxidation is selectively involved in progressive supranuclear palsy.  J Exp Neurol Neuropathol . 2000;  59 393-397
    PubMedGoogle Scholar
  • 54 Albers D S, Augood S J, Park L C. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment.  J Neurochem . 2000;  74 878-881
    CrossrefPubMedGoogle Scholar
  • 55 Swerdlow R H, Golbe L I, Parks J K. Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with progressive supranuclear palsy.  J Neurochem . 2000;  75 1681-1684
    CrossrefPubMedGoogle Scholar
  • 56 Albers D S, Augood S J, Martin D M. Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy.  J Neurochem . 1999;  73 881-884
    CrossrefPubMedGoogle Scholar
  • 57 Loeffler D A, LeWitt P A, Juneau P L. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders.  Brain Res . 1996;  738 265-274
    CrossrefPubMedGoogle Scholar
  • 58 Sian J, Dexter D T, Lees A J. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.  Ann Neurol . 1994;  36 348-355
    CrossrefPubMedGoogle Scholar
  • 59 Smith M A, Kutty R K, Richey P L. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease.  Am J Pathol . 1994;  145 42-47
    PubMedGoogle Scholar
  • 60 Jenner P. Oxidative stress in Parkinson's disease and other neurodegenerative disorders.  Pathol Biol (Paris) . 1996;  44 57-64
    PubMedGoogle Scholar
  • 61 Kordower J H, Palfi S, Chen E Y. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease.  Ann Neurol . 1999;  46 419-424
    CrossrefPubMedGoogle Scholar
  • 62 Lieberman D M, Laske D W, Morrison P, Bankiewicz K S, Oldfield E H. Convection-enhanced distribution of large molecules in gray matter during interstitial infusion.  J Neurosurg . 1995;  82 1021-1029
    PubMedGoogle Scholar
  • 63 Litvan I, Dickson D W, Buttner-Ennever J A, participants in the First International Brainstorming Conference on PSP. Research goals in progressive supranuclear palsy.  Mov Disord . 2000;  15 446-458
    CrossrefPubMedGoogle Scholar
      >